- Home
- SACH vs AKTX Comparison
SACH vs AKTX Comparison
Compare SACH & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- AKTX
- Stock Information
- Founded
- SACH 2010
- AKTX N/A
- Country
- SACH United States
- AKTX United States
- Employees
- SACH N/A
- AKTX N/A
- Industry
- SACH Real Estate Investment Trusts
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- AKTX Health Care
- Exchange
- SACH Nasdaq
- AKTX Nasdaq
- Market Cap
- SACH 46.7M
- AKTX 41.8M
- IPO Year
- SACH 2017
- AKTX N/A
- Fundamental
- Price
- SACH $1.18
- AKTX $1.17
- Analyst Decision
- SACH Hold
- AKTX
- Analyst Count
- SACH 3
- AKTX 0
- Target Price
- SACH $2.25
- AKTX N/A
- AVG Volume (30 Days)
- SACH 229.8K
- AKTX 28.8K
- Earning Date
- SACH 08-13-2025
- AKTX 08-18-2025
- Dividend Yield
- SACH 16.81%
- AKTX N/A
- EPS Growth
- SACH N/A
- AKTX N/A
- EPS
- SACH N/A
- AKTX N/A
- Revenue
- SACH N/A
- AKTX N/A
- Revenue This Year
- SACH N/A
- AKTX N/A
- Revenue Next Year
- SACH $4.52
- AKTX N/A
- P/E Ratio
- SACH N/A
- AKTX N/A
- Revenue Growth
- SACH N/A
- AKTX N/A
- 52 Week Low
- SACH $0.80
- AKTX $0.85
- 52 Week High
- SACH $3.07
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- SACH 60.46
- AKTX 44.98
- Support Level
- SACH $1.08
- AKTX $1.15
- Resistance Level
- SACH $1.12
- AKTX $1.22
- Average True Range (ATR)
- SACH 0.06
- AKTX 0.08
- MACD
- SACH -0.00
- AKTX -0.00
- Stochastic Oscillator
- SACH 65.91
- AKTX 40.86
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.